Načítá se...
Ertugliflozin in the treatment of type 2 diabetes mellitus
More than 422 million people worldwide have diabetes, with 90–95% having type 2 diabetes (T2D). Glycemic control of T2D has demonstrated reductions in microvascular complications but recent data have demonstrated improvements in macrovascular outcomes with sodium–glucose cotransporter 2 (SGLT2) inhi...
Uloženo v:
| Vydáno v: | Drugs Context |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioExcel Publishing Ltd
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7707814/ https://ncbi.nlm.nih.gov/pubmed/33293984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-7-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|